期刊文献+

四色流式细胞术分析多发性骨髓瘤的免疫表型与临床特征及预后关系 被引量:1

Four-color flow cytometric analysis of multiple myeloma and the correlation with its clinical features and prognosis
原文传递
导出
摘要 目的:利用四色流式术探讨多发性骨髓瘤(MM)免疫表型与临床特征的相关性及其预后价值。方法:分别用四色流式细胞术、间期荧光原位杂交技术检测50例初诊MM患者的瘤细胞表面免疫表型以及细胞遗传学异常,并收集患者的临床和实验室指标。结果:共检测不同组合的四色CD抗原:CD38-PE/CD45-Percp/CD19-FITC/CD56-APC;CD38-FITC/CD138-Percp/CD117-PE/CD28-APC;CD38-PE/CD138-Percp/CD27-APC/CD20-FITC,其中CD28的表达多与ISS高分期相关,多易骨髓浸润,出现贫血、高钙、肾功能损害、低白蛋白、β2-微球蛋白高水平,以及IGH易位等不良预后因素,而CD117则为较佳预后因素,其表达缺失患者多易出现骨髓浸润,低白蛋白,且易出现del(13q14),IGH易位,进一步分析发现del(13q14)与IGH易位之间存在相关性(r=0.378,P<0.05);分别根据CD28和CD117的联合表达以及FISH预后风险分组,流式高危组(CD28+CD117-)与FISH预后风险分组中的高危组(13q14缺失)之间差异有统计学意义(P<0.05)。结论:CD28和CD117对MM患者的临床预后具有重要的价值,且其联合评估能够帮助MM患者识别预后因素,指导临床治疗。 Objective:This study was purposed to investigate the relation between the immunophenotype and clinical features or prognosis in multiple myeloma(MM).Method:The immunophenotype and cytogenetic abnormalities of myeloma cell of 50 cases of newly diagnosed MM patients were detected with multiparameter flow cytometry(MFC) and interphase fluorescence in situ hybridization(I-FISH)respectively.The clinical and laboratory parameters of the patients were colleted and analyzed as well.Result:In this study,different antigen combinations were detected: CD38-PE/CD45-Percp/CD19-FITC/CD56-APC,CD38-FITC/CD138-Percp/CD117-PE/CD28-APC,CD38-PE/CD-138-Percp/CD27-APC/CD20-FITC.Expression of CD28 was associated with a significant higher frequency of advanced International staging system(ISS) stages,higher levels of BM infiltration(PC≥30%)and β2-microglobulin(β2-MG≥0.2 g/L),greater frequencies of anemia(Hemoglobin≤100 g/L),hypercalcemia(calcium≥2.75 mmol/L),renal impairment(creatinine≥0.2 g/L),low albumin(albumin≤30 g/L),and IGH translocations.In turn,lack of CD117 expression was associated with higher levels of BM infiltration,greater frequencies of low albumin,del(13q14) and IgH translocations.Further analysis revealed that there was correlation between del(13q14) and IGH translocation(r=0.378,P〈0.05).Grouped according to the joint expression of CD28 and CD117 or the risk stratification of FISH,we found that there was significant difference between the CD28+CD117-group and del(13q14) group(P〈0.05).Conclusion:The expression of CD28 and CD117 has important clinical prognosis value for MM patients,which helps for identifying the prognostic factors and guiding clinical treatment in MM.
出处 《临床血液学杂志》 CAS 2012年第4期430-433,436,共5页 Journal of Clinical Hematology
关键词 多发性骨髓瘤 流式细胞术 免疫表型 临床特征 预后 multiple myeloma multiparameter flow cytometry immunophenotype clinical features prognosis
  • 相关文献

参考文献20

  • 1张之南,沈悌.血澉病诊断及疗效标准[M].3版.北京:科学出版社,2007:232-23.
  • 2MATEO G,MONTALBAN M A,VIDRIALES M B, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy [J]. J Crm Oncol , 2008, 26: 2737-2744.
  • 3DISPENZIERI A,RAIKUMAR S V,GERTZ M A,et al. Treatment of newly diagnosed multiple mvclorna based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensves staement [J]. Mayo Clin Proc , 2007 ,82: 323 - 341.
  • 4RAWSTRON A C,DAVIES F E,DASGUPTA R,et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplau tation[J]. Blood,2002,100: 3095-3100.
  • 5RAWSTRON A C, ORFAO A, BEKSAC M, Report of the European Myeloma Networket multaramctric flow cytornet ry in multiple myelosea and telated disorders [J]. Haornatologica , 2008, 23: 431-438.
  • 6陈葆国,罗文达,李伯利,郑瑞,颜卫华,石卫武.多发性骨髓瘤流式细胞术免疫表型及微量残留病研究[J].中华检验医学杂志,2011,34(1):10-14. 被引量:8
  • 7CAO W,GOOLSBY C L.NENLSON B P.et al. Instability of irnrnunophcnotype in plasma cell myeloma [J]. Am J Clin Pathol.2008.129: 926-933.
  • 8KUMAR S. KIMLINGER T. MORICE W. Immuno phenotyping in multiple myeloma and related plasms cell disorders [J]. Best Pract Res Clin Haematol , 2010,23: 433-451.
  • 9PAIVA B.ALMEIDA J,PEREZ-ANDRES M,et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders[J]. Cytometry B Clin Cytom , 2010,78: 239-252.
  • 10RAJA K R, KOVAROVA L, HAJEK R. Review of phenotypic markers used in flow cytomctric ansly of MGlTS and MM, and applicability of flow cytornctry in other plasma cell disorders[J]. Br J Haematol , 2010.119: 334-351.

二级参考文献9

  • 1Child JA,Morgan GJ,Davies FE,et al.High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma.N Engl J Med,2003,348:1875-1883.
  • 2Sun RX,Lu ZY,Wijdenes J,et al.Large scale and clinical grade purification of syndecan-1 + malignant plasma cells.J Immunol Methods,1997,205:73-79.
  • 3Rawstron AC,Orfao A,Beksac M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Haematologica,2008,93:431-438.
  • 4Lin P,Owens R,Tricot G,et al.Flow Cytometric immunophenotypic analysis of 306 cases of multiple myeloma.Am J Clin Pathol,2004,121:482-488.
  • 5San Miguel JF,Almeida J,Mateo G,et al.Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma:a tool for comparing the efficacy of different treatment strategies and predicting outcome.Blood,2002,99:1853-1856.
  • 6Lima M,Teixeira MA,Fonseca S,et al.Immunophenotypic aberrations,DNA content,and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.Blood Cells Mol Dis,2000,26:634-645.
  • 7Rawstron AC,Davies FE,DasGupta R,et al.Flow cytometric disease monitoring in multiple myeloma:the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.Blood,2002,100:3095-3100.
  • 8Gupta R,Bhaskar A,Kumar L,et al.Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma.Am J Clin Pathol,2009,132:728-732.
  • 9Carlo-Stella C,Guidetti A,Dinicola M,et al.CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vitro in NOD/SCID mice.Exp Hematol,2006,34:721-727.

共引文献7

同被引文献6

  • 1李娟,罗绍凯,张国材,洪文德,童秀珍.CD_(117)在多发性骨髓瘤细胞中的表达及其意义[J].癌症,2004,23(8):951-954. 被引量:7
  • 2Durie BG,Salmon SE. A clinical staging system for multiple mye- loma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival [ J ]. Cancer, 1975,36(3) :842-854. DOI: 10. 1002/1097142(197509)36:3 < 842 : : AID-CNCR2820360303 > 3.0. CO ;2-U.
  • 3Rawstron AC, Orfao A, Beksac Met al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple- myeloma and related disorders[J]. Haematologica,2008, 93 ( 3 ) : 431-438. DOI : 10. 3324/haematol. 11080.
  • 4Paiva B, Vidriales MB, Perez JJ, et al. Multiparameter flow cy- tometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assess- ment in myeloma patients. [J ] Haematalogica, 2009,94 ( 11 ) : 1599-1602. DOI : 10. 3324/haematol. 2009. 009100.
  • 5李娟,黄蓓晖,赵莹,罗绍凯.伊马替尼诱导c—kit阳性多发性骨髓瘤细胞凋亡[J].中华血液学杂志,2008,29(4):230-233. 被引量:3
  • 6胡淑芬,谭冬梅,孙文洪,陈慧谊,谢伟成.21例多发性骨髓瘤患者临床分析[J].中华实用诊断与治疗杂志,2011,25(5):478-480. 被引量:10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部